Close
Novotech
Jabsco PureFlo 21 Single Use
Drug Research

Meridian, Teva settle epinephrine auto-injector pending patent litigation

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Drug Research

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.
Drug Research

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.
BioPharma

The Hidden Cost of Licensing in Biologic Drug Development

Royalties, milestone payments, and license fees are often treated as the cost of doing business in biopharma. But for early-stage biotech companies building toward an IND, these obligations can quietly reshape financial models, complicate investor conversations, and create downstream deal terms that are difficult to unwind. Here is what founders need to know.
- Advertisement -

Meridian Medical Technologies, a Pfizer subsidiary, and Teva have entered into a settlement agreement to resolve generic epinephrine auto-injector pending patent litigation.

Under the terms of the agreement, Teva may launch a generic epinephrine auto-injector covered by its ANDA on 22 June 2015 or earlier under certain circumstances, subject to receipt of approval from the FDA. Additional terms of the agreement, which is subject to review by the US Department of Justice and the Federal Trade Commission, have not been disclosed. Teva presently does not have tentative FDA approval for its epinephrine auto-injector product. Meridian manufactures EpiPen Auto-Injector while Mylan Specialty markets and distributes the product in the US.

Latest stories

Previous article
Affymax, Takeda launch OMONTYS injection in US
Next article
Antares, Watson Pharmaceuticals launch Gelnique 3% in US

Related stories

Drug Research

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.
Drug Research

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.
BioPharma

The Hidden Cost of Licensing in Biologic Drug Development

Royalties, milestone payments, and license fees are often treated as the cost of doing business in biopharma. But for early-stage biotech companies building toward an IND, these obligations can quietly reshape financial models, complicate investor conversations, and create downstream deal terms that are difficult to unwind. Here is what founders need to know.
Clinical Trials

Early Phase Decisions Drive Faster Drug Development

Strategic early-stage planning and rigorous regulatory readiness serve as the foundation for accelerating pharmaceutical timelines and optimizing long-term R&D efficiency.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

About us

World Pharma Today is a leading Magazine featuring latest industry developments for the Pharmaceutical C-level executives. . . Read More

SUBSCRIBE US

System

RESOURCES

ARCHIVE LINKS

Subscribe

Copyright © 2010-2026 World Pharma Today. All rights reserved. Publication of Leo Marcom Pvt Ltd.

Translate »
MORE STORIES
mobile field hospitals emergency healthcare

How Mobile Field Hospitals Are Changing Emergency Care

Husky SEM Plastik blood collection tubes

Husky and SEM Plastik Announce Strategic Collaboration to Advance Blood Collection...